Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Nederlof

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Nature Genetics|November 4, 2000
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancersJ J Jacobs, P Keblusek, E Robanus-Maandag, et al.
Breast Cancer Research and Treatment|February 3, 2011
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patientsM A Didraga, E H van Beers, S A Joosse, et al.
British Journal of Cancer|October 10, 2002
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approachJ J P Gille, F B L Hogervorst, G Pals, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Journal of Clinical Pathology|June 29, 2004
Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samplesF B J M Thunnissen, M G J Tilanus, M J L Ligtenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2010
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsM A Vollebergh, E H Lips, P M Nederlof, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Nature Genetics|November 4, 2000
Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancersJ J Jacobs, P Keblusek, E Robanus-Maandag, et al.
Breast Cancer Research and Treatment|February 3, 2011
A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patientsM A Didraga, E H van Beers, S A Joosse, et al.
British Journal of Cancer|October 10, 2002
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approachJ J P Gille, F B L Hogervorst, G Pals, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Molecular Tumor Boards: current practice and future needsD L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Journal of Clinical Pathology|June 29, 2004
Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samplesF B J M Thunnissen, M G J Tilanus, M J L Ligtenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2010
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsM A Vollebergh, E H Lips, P M Nederlof, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Pageof 3